Lacosamida Alembic

Lacosamide, the active ingredient in Lacosamida Alembic, is a sodium channel blocker presented as an oral dosage form for oral use. It treats partial‑onset seizures as adjunctive therapy in patients with epilepsy, helping to reduce seizure frequency and improve overall neurological stability.

GNH USA supplies Lacosamida Alembic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across the European market and beyond.

Lacosamide is employed in the management of epilepsy, specifically targeting neuronal hyperexcitability associated with partial‑onset seizures. - Partial‑onset seizures: reduces seizure frequency as adjunctive therapy. - Adjunctive therapy for epilepsy: enhances seizure control when added to existing antiepileptic regimens. - Focal epilepsy: improves overall seizure management in patients with focal seizure types. - Refractory epilepsy: provides additional seizure reduction for patients whose seizures are not adequately controlled by other agents.

Common Side Effects: - Dizziness - Nausea - Fatigue - Headache Serious or Rare Side Effects: - Cardiac arrhythmias, including supraventricular tachycardia - Severe skin reactions such as Stevens‑Johnson syndrome - Liver enzyme elevations indicating hepatic stress - Rare cases of hypersensitivity reactions requiring immediate medical attention

Renal impairment: adjust dosing under medical supervision. Hepatic dysfunction: monitor liver function tests regularly. Cardiac history: obtain baseline ECG and monitor for conduction abnormalities. Concomitant CNS depressants: observe for additive sedation or respiratory depression. Pregnancy and breastfeeding: use only if potential benefits outweigh potential risks. Store at ambient temperature: keep in original container, protect from moisture and light.

Major Interactions (Avoid): - Carbamazepine: may reduce lacosamide plasma concentrations. - Phenobarbital: may decrease therapeutic efficacy. - Rifampin: may lower drug levels, compromising seizure control. Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): increased sedation risk. - Anticoagulants (e.g., warfarin): monitor INR for potential alterations. - Hormonal contraceptives: possible reduced effectiveness, consider alternative contraception.